<DOC>
	<DOCNO>NCT02118337</DOCNO>
	<brief_summary>To evaluate safety , tolerability antitumor activity MEDI0680 ( AMP-514 ) give combination MEDI4736 MEDI0680 monotherapy .</brief_summary>
	<brief_title>A Phase 1/2 , Open-label Study Evaluate Safety Antitumor Activity MEDI0680 ( AMP-514 ) Combination With MEDI4736 MEDI0680 Monotherapy Subjects With Select Advanced Malignancies</brief_title>
	<detailed_description>This multicenter , open-label , dose-escalation , dose expansion study MEDI0680 give alone combination MEDI4736 evaluate safety , tolerability , pharmacokinetic ( PK ) , immunogenicity , antitumor activity adult subject select advanced malignancy .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Must 18 year old Eastern Cooperative Oncology Group performance status 01 Adequate organ function No 1 prior line therapy Concurrent enrollment another clinical study , unless followup period observational study Concurrent chemotherapy , immunotherapy , biologic , hormonal therapy cancer treatment Prior treatment immunotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>select advance malignancy</keyword>
</DOC>